Drug Type Small molecule drug |
Synonyms Bipyrocycline |
Target |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors), Protein synthesis inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H36N4O7 |
InChIKeyYOOGAONNHXDMEQ-OMBSCLNISA-N |
CAS Registry1420294-56-9 |
Start Date16 Aug 2022 |
Sponsor / Collaborator |
Start Date11 Aug 2020 |
Sponsor / Collaborator |
Start Date01 Oct 2015 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bacterial Infections | Phase 1 | US | 28 Apr 2015 | |
Complicated skin and soft tissue infection | Phase 1 | - | - | |
Diabetic Foot | Phase 1 | - | - | |
Intraabdominal Infections | Phase 1 | - | - | |
Pneumonia | Phase 1 | - | - | |
Urinary Tract Infections | Phase 1 | - | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |